Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis.
The effect of corticosteroid therapy in 28 patients with 52 episodes of neuropyciatric disease in systemic lupus erythematosus (SLE) was elevated. Categories of organic central nervous system disease were seizures (eight patients), organic brain syndromes (nine patients), aseptic meningitis (four patients) and a variety of focal neurologic findings (seven patinets). Fourteen pateints had 15 episodes of functional psychosis without other evidence of neurologic disease. Although there was a general correlation between clinical and serologic evidnce of active SLE and the development of organic neurolgic disease, there was no evidence that therapy with very large doses of corticosteroids was beneficial. Of the deaths in this series, two were due to probable active SLE involving the central nervous system wheras five were attributable to complications of therapy. The long-term morbidity, likewise, was high in the patients who recieved large doses of corticosteroids. In all, 12 patients had major complications of corticosteroid therapy. Functional psychosis was usually preciptated by corticsoteroid therapy and respond to a reduction in steroid dosage and administration of psychotropic drugs.
D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000009:adverse effects; D002493:Central Nervous System Diseases / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008581:Meningitis / Q000150:complications; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011619:Psychotropic Drugs / Q000627:therapeutic use
D011619:Psychotropic Drugs; D001379:Azathioprine; D011241:Prednisone